On this page
What are Nasal Polyps?
Nasal polyps are soft, painless, non-cancerous (benign) growths that develop on the lining of the nasal passages or sinuses. They are typically teardrop-shaped, pearly or yellowish in color, and vary in size. Many people with small nasal polyps are completely unaware of their presence because they may cause no symptoms whatsoever.
When polyps grow larger, or when many small polyps appear at the same time, they can partially or completely block the nasal passages and sinuses. This blockage leads to a range of troublesome symptoms:
- Nasal congestion (blocked nose)
- Anosmia or hyposmia (complete or partial loss of smell)
- Runny nose (rhinorrhea) and post-nasal drip
- Frequent sinus infections (sinusitis)
- Facial pressure or discomfort
- Snoring and disrupted sleep
- Less commonly, facial pain or headache
When nasal breathing becomes significantly obstructed, patients are forced to breathe predominantly through the mouth, which can be especially disruptive at night, leading to poor sleep quality and daytime fatigue.
Although nasal polyps can affect anyone, they are most common in adults and are more frequently found in people who have:
- Asthma
- Recurrent or chronic sinus infections (sinusitis)
- Allergic rhinitis or other allergies
Children rarely develop nasal polyps except in the context of cystic fibrosis, where they are a recognized complication.
Treatment options include medications (to shrink or occasionally eliminate polyps) and surgery when medical therapy is insufficient. While most symptoms improve significantly after treatment, the sense of smell may not fully recover in patients who have had prolonged anosmia. Importantly, nasal polyps often recur; in fact, some studies show that up to 70% of operated patients experience a relapse. This makes long-term management and follow-up essential.
Causes
The nasal cavity and paranasal sinuses are lined with mucosa, a specialized tissue that produces mucus and is densely supplied with blood vessels. Its surface is covered with tiny hair-like structures called cilia, which work together with mucus to trap and clear airborne particles, bacteria, and allergens before they reach the lower airways. During inhalation, air passes through the nasal passages, where it is warmed, humidified, and filtered. This process is vital, but polyps can severely compromise it.
Although the exact cause of nasal polyp formation has not been fully established, the leading theory is that they arise as a result of chronic inflammation of the nasal and sinus mucosa. By definition, inflammation is considered chronic when signs and symptoms persist for more than 12 weeks. A sustained immune response, particularly one driven by a type 2 inflammatory pattern (which is characterized by the activity of interleukins IL-4, IL-5, and IL-13, along with elevated eosinophils and IgE), appears to play a central role in the pathogenesis of nasal polyps.
Polyps can develop in any area of the nasal cavity or sinuses, but the region near the paranasal sinuses (especially the ethmoid sinuses, near the eyes) is the most commonly affected.
Risk Factors
Nasal polyps are primarily a condition of adulthood and are significantly more common in men than women (with a male-to-female ratio of approximately 2:1–3:1). They are rare in children and, when present in pediatric patients, should raise clinical suspicion for cystic fibrosis.
There may be a genetic predisposition: some individuals appear to have a hereditary tendency to develop chronic mucosal inflammation, though specific genes have not yet been definitively identified.
The following conditions and factors are known to increase the risk of nasal polyp formation:
-
Asthma: A chronic inflammatory disease of the airways. Between 20% and 40% of individuals with nasal polyps are also asthmatic, reflecting a shared underlying inflammatory mechanism known as the “unified airway” concept.
-
Aspirin-exacerbated respiratory disease (AERD): Also known as Samter’s triad, this condition involves sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen. Ingestion of these drugs triggers allergy-like respiratory reactions. This triad of asthma, nasal polyps, and NSAID sensitivity is a particularly challenging clinical phenotype.
-
Chronic rhinosinusitis (CRS): Persistent inflammation of the sinuses is one of the most important predisposing conditions.
-
Allergic fungal sinusitis: An exaggerated immune response to airborne mold spores can fuel the chronic inflammation that predisposes to polyp formation.
-
Cystic fibrosis: This genetic disease leads to abnormally thick mucus secretions in the respiratory tract. As a result, affected individuals, including children, are more likely to develop nasal polyps.
-
Rare genetic syndromes: Conditions such as primary ciliary dyskinesia (Kartagener syndrome) and Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) are associated with an increased risk.
Symptoms
Small nasal polyps frequently cause no symptoms and may only be discovered incidentally during examination for another condition. When polyps grow larger, become more numerous, or do both, they may obstruct airflow and trigger symptoms similar to those of a common cold. However, unlike a cold, the symptoms of nasal polyps persist for weeks, months, or even years.
Common symptoms include:
- Nasal congestion and difficulty breathing through the nose.
- Runny nose (persistent rhinorrhea).
- Post-nasal drip (mucus draining down the back of the throat).
- Reduced or absent sense of smell (hyposmia/anosmia).
- Reduced sense of taste (often a consequence of impaired smell).
- Facial pressure or heaviness around the eyes, cheeks, and forehead.
- Snoring.
- Headache.
- Obstructive sleep apnea: recurrent episodes of breathing interruption during sleep.
Nasal polyps can also predispose patients to recurrent sinusitis, manifesting as facial pain, toothache, fever, and thick discolored nasal discharge.
When to See a Doctor
Because the symptoms of nasal polyps overlap significantly with those of the common cold and allergic rhinitis, many patients delay seeking medical attention. A key distinguishing feature is duration: while a cold typically resolves within 7–10 days, symptoms caused by nasal polyps persist for weeks or months.
Seek medical advice if:
- Nasal congestion, loss of smell, or other symptoms persist for more than 10–12 weeks
- Symptoms progressively worsen despite over-the-counter treatments
- You experience recurrent sinus infections
Contact your doctor promptly if:
- Polyps are present on only one side of the nose. Unilateral polyposis is uncommon, so it should always be evaluated to rule out more serious causes, such as tumors.
- You notice nosebleeds that are unexplained or persistent (though these can also result from mucosal irritation or incorrect use of nasal sprays).
- Symptoms of sinusitis develop (fever, facial pain, thick nasal discharge).
Call emergency services (911 or your local emergency number) immediately if you experience sudden or severe difficulty breathing.
Diagnosis
The diagnostic workup for nasal polyposis follows well-established clinical protocols, aiming not only to confirm the presence of polyps but also to assess their extent, underlying causes, and impact on respiratory function. An early and accurate diagnosis allows for the most targeted and effective treatment strategy.
Medical History and Clinical Assessment
The physician begins by gathering a thorough medical history, focusing on:
- Duration of symptoms (chronicity is defined as persistence beyond 12 weeks)
- Quality and pattern of nasal breathing
- Presence and severity of smell loss
- History of asthma, allergies, or prior sinus infections
- Use of aspirin or NSAIDs and any associated reactions
- Family history of nasal polyps or related conditions
- Previous nasal or sinus surgery
A standardized questionnaire such as the SNOT-22 (Sino-Nasal Outcome Test) is often used to quantify the impact of symptoms on the patient’s quality of life.
Nasal Endoscopy
Nasal endoscopy is the gold standard for diagnosing nasal polyps. It is performed by an ENT (ear, nose, and throat) specialist using a thin, flexible or rigid tube with a micro-camera (endoscope) inserted into the nostrils.
This procedure allows the clinician to:
- Directly visualize the polyps
- Assess their location, size, color, and number
- Identify mucopurulent secretions from the sinus ostia
- Stage the disease using validated systems (e.g., the Lund-Kennedy endoscopic scoring system)
The procedure is well-tolerated and typically performed in an outpatient clinic setting, sometimes following application of a topical decongestant or anesthetic spray.
Radiological Imaging
-
Computed Tomography (CT) scan: This is the essential radiological investigation for nasal polyposis, usually performed without contrast medium. CT provides detailed three-dimensional mapping of the paranasal sinuses, is indispensable for pre-surgical planning, and allows the surgeon to identify anatomical variants, the extent of disease, and the degree of sinus involvement (graded using the Lund-Mackay scoring system).
-
Magnetic Resonance Imaging (MRI): Used selectively, primarily to differentiate nasal polyps from other lesions such as tumors, meningoceles, or encephaloceles. It is also helpful for evaluating complications that extend to the orbit or skull base.
Biomarkers and Specialist Tests
In patients with severe or recurrent polyposis, assessing the patient’s inflammatory profile has become standard practice, especially given the availability of targeted biologic therapies:
- Blood eosinophil count: Elevated eosinophils suggest a type 2 inflammatory endotype, which tends to be associated with more severe and recurrent disease and better response to certain biologics.
- Total serum IgE: Useful to characterize the allergic component of inflammation.
- Allergy skin prick testing or specific IgE blood tests: To identify relevant allergen sensitivities.
- Aspirin/NSAID challenge: In cases where AERD is suspected.
- Biopsy: Indicated for unilateral or atypical polyps to exclude malignancy or other pathologies (e.g., inverted papilloma, lymphoma).
- Sweat chloride test or genetic testing: In children with polyps, to rule out cystic fibrosis.
Risks and Complications
When numerous or very large nasal polyps are present (a condition called polyposis), they can significantly disrupt normal nasal and sinus function, leading to complications that extend well beyond nasal obstruction:
-
Recurrent or chronic sinusitis: Blocked sinus drainage creates an environment where bacteria and fungi thrive, leading to frequent and difficult-to-treat infections.
-
Obstructive sleep apnea (OSA): A serious condition characterized by recurrent episodes of breathing cessation during sleep, associated with cardiovascular risk, daytime sleepiness, and impaired cognitive function.
-
Worsening of asthma: Nasal obstruction forces mouth breathing, bypassing the warming and filtering function of the nose, which can exacerbate lower airway inflammation.
-
Loss of smell (anosmia): This can become permanent if the olfactory epithelium is damaged by prolonged inflammation.
-
Aesthetic and structural deformity: In extreme cases of massive, untreated polyposis, continuous growth can cause visible widening of the nasal bridge (the so-called “frog face” or “potato nose” deformity), and may even erode surrounding bony structures.
Treatment
The management of nasal polyposis has evolved significantly in recent years toward a personalized, step-up approach that targets the underlying inflammation, aims to restore nasal airflow and smell, and works to prevent post-treatment recurrence. The choice of treatment depends on polyp size, symptom severity, inflammatory profile, and response to prior therapies.
First-Line Drug Therapy
Medications are almost always the starting point of treatment:
-
Intranasal corticosteroids (INCs): Available as sprays, drops, or medicated nasal rinses, these represent the cornerstone of long-term therapy. They reduce local mucosal inflammation and can shrink small polyps. Examples include mometasone furoate, fluticasone propionate, and budesonide. Correct technique is essential to maximize drug delivery to the affected mucosa.
-
Systemic corticosteroids: Short courses of oral corticosteroids (such as prednisone or prednisolone) can rapidly reduce the size of large polyps. These are sometimes called a medical polypectomy. However, their use is limited to short intervals, usually 5 to 14 days, because prolonged use carries the risk of significant side effects. These may include weight gain, hypertension, osteoporosis, and adrenal suppression.
Innovative Therapies: Biologic Drugs
One of the most important advances in the treatment of severe nasal polyposis in recent years has been the introduction of targeted biologic therapies. These therapies include monoclonal antibodies, which block key molecules that drive type 2 inflammation.
- Dupilumab (anti-IL-4/IL-13): Approved for chronic rhinosinusitis with nasal polyps (CRSwNP) in adults; significantly reduces polyp size, improves smell, and reduces the need for surgery or systemic steroids.
- Omalizumab (anti-IgE): Particularly useful in patients with concomitant allergic asthma.
- Mepolizumab (anti-IL-5): Targets eosinophilic inflammation; approved for severe CRSwNP in several countries.
These medications are administered by subcutaneous injection and are reserved for patients with severe CRSwNP who have failed corticosteroid treatment and/or previous surgery, or who have contraindications to surgery. They represent a major therapeutic breakthrough, particularly for patients with high recurrence rates.
Surgical Treatment (FESS)
When medical therapy alone fails to adequately control symptoms or reduce polyp burden, surgery is indicated. The procedure of choice is Functional Endoscopic Sinus Surgery (FESS).
FESS is performed under general anesthesia using nasal endoscopes and precision micro-instruments. These tools include the microdebrider, which is a powered oscillating blade, and they allow the surgeon to:
- Remove nasal polyps
- Open obstructed sinus ostia to restore drainage and ventilation
- Preserve as much healthy mucosa as possible
- Minimize trauma to surrounding structures (orbit, skull base)
No external incisions are required. FESS is performed entirely through the nostrils. Recovery is generally rapid, with most patients returning to normal activities within 1–2 weeks.
Important caveat: Surgery removes the consequence of the underlying inflammation (the polyps), but not the cause. Long-term medical therapy, which usually includes intranasal corticosteroids and regular saline rinses, must be continued after surgery to reduce the risk of recurrence. In patients with high-risk profiles, biologic therapy after surgery may be recommended.
Lifestyle Measures and Supportive Remedies
Daily self-management plays an important role in controlling symptoms and reducing inflammation:
-
Nasal saline irrigation: Regular rinsing with isotonic or hypertonic saline solution using a neti pot, squeeze bottle, or pressure irrigation device is highly recommended. It mechanically removes excess mucus, allergens, and inflammatory mediators, enhances mucociliary clearance, and improves the penetration of topical corticosteroid sprays.
-
Environmental control: Avoiding known triggers, such as cigarette smoke (active and passive), air pollutants, occupational irritants, and allergens, helps prevent further mucosal irritation.
-
Humidification: Maintaining appropriate indoor humidity levels (40–50%) prevents mucosal dryness and facilitates normal mucus drainage.
-
Managing underlying conditions: Treating comorbidities such as allergic rhinitis and asthma with appropriate medications is essential to controlling the shared inflammatory substrate.
Prevention
While it is not possible to completely prevent nasal polyps, the following strategies can help reduce the likelihood of their development or recurrence by targeting the chronic inflammation believed to underlie their formation:
-
Treat underlying conditions proactively: Managing asthma, allergies, and rhinosinusitis with appropriate, regular therapy reduces mucosal inflammation and lowers the risk of polyp development.
-
Minimize exposure to irritants and allergens: Avoid cigarette smoke, air pollutants, mold, dust mites, and occupational chemical irritants that can chronically inflame the nasal mucosa.
-
Practice good hand hygiene and maintain a healthy lifestyle: Preventing upper respiratory tract infections, which can trigger or worsen nasal inflammation, is an important indirect preventive measure.
-
Perform regular nasal saline rinses: Daily or twice-daily irrigation with saline helps maintain mucosal health and prevent the accumulation of inflammatory mediators.
-
Humidify indoor environments: This supports proper nasal function and mucus drainage.
-
Use intranasal corticosteroid sprays as prescribed: For patients with a known history of nasal polyps, long-term use of prescribed corticosteroid nasal sprays remains the most evidence-based strategy to prevent recurrence following medical or surgical treatment.
-
Attend regular follow-up appointments: Periodic endoscopic evaluation allows early detection of recurrent polyps before they become large and symptomatic, enabling earlier and less aggressive intervention.
Frequently Asked Questions
What are nasal polyps?
Nasal polyps are soft, painless, benign (non-cancerous) growths that develop on the lining of the nose or sinuses. They are not dangerous in themselves but can grow large enough to obstruct the nasal passages, causing breathing difficulties, loss of smell, and recurrent infections.
What symptoms do nasal polyps cause?
Nasal polyps can cause several symptoms, including nasal congestion (blocked nose), a runny nose, post-nasal drip, a reduced or absent sense of smell, and a reduced sense of taste. They may also lead to snoring, nosebleeds, and, if large or numerous, obstructive sleep apnea.
How can nasal polyps be identified?
Small polyps may not be visible to the naked eye when looking into the nostrils. When visible, they appear as pearly-white or yellowish, smooth, soft, fleshy growths. Definitive identification requires nasal endoscopy performed by an ENT specialist.
How can nasal polyps be reduced in size?
The first-line treatment for reducing polyp size is intranasal corticosteroid sprays. For larger polyps, a short course of oral corticosteroids may be prescribed. In cases of severe or refractory polyposis, biologic drugs (such as dupilumab) have shown significant efficacy in reducing polyp volume.
Can nasal polyps be permanently eliminated?
Complete and permanent elimination of nasal polyps is difficult to achieve. Medications can shrink or sometimes eliminate small polyps, but recurrence is common. Surgery (FESS) can remove nasal polyps effectively, but recurrence rates are high. Some studies report rates as high as 70%, particularly in patients with severe disease, asthma, or AERD. Ongoing medical therapy is essential to minimize the risk of recurrence.
Is there always a risk of recurrence after treatment?
Yes. Nasal polyps have a well-documented tendency to recur, especially in patients with underlying type 2 inflammation, asthma, or NSAID sensitivity. This is why long-term follow-up and continued medical management, whether or not subsequent biologic therapy is used, are fundamental parts of the treatment plan.
What should I do if I suspect I have nasal polyps but cannot see a doctor immediately?
Do not self-medicate without medical guidance. While waiting for your specialist appointment, you may discuss with your general practitioner whether saline nasal rinses and an over-the-counter or prescribed intranasal corticosteroid spray are appropriate as a temporary measure. Avoid using nasal decongestant sprays (oxymetazoline, xylometazoline) for more than 3–5 consecutive days, as they can worsen nasal congestion in the long term (rhinitis medicamentosa).
Sources and Bibliography
- European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS)
- A review of nasal polyposis – NIH/PubMed
- Nasal Polyposis: Current Trends – NIH/PubMed
- Mayo Clinic – Nasal Polyps
- NHS – Nasal Polyps
- American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) – Clinical Practice Guideline: Adult Sinusitis
- Fokkens WJ et al. EPOS 2020: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
- Bachert C et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2021.
